Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy Study of Oral Sorbitol to Enhance the Therapeutic Effect of Neoadjuvant Chemotherapy Combined with Tirellizumab (PD-1 Inhibitor) in Patients with Locally Advanced Gastric Cancer

Next Previous
Trial Profile

Safety and Efficacy Study of Oral Sorbitol to Enhance the Therapeutic Effect of Neoadjuvant Chemotherapy Combined with Tirellizumab (PD-1 Inhibitor) in Patients with Locally Advanced Gastric Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Sorbitol (Primary) ; Tislelizumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms SNCCTGC

Most Recent Events

  • 18 Aug 2026 Planned number of patients changed from 80 to 86.
  • 18 Aug 2026 Planned End Date changed from 1 Aug 2028 to 1 Aug 2029.
  • 18 Aug 2026 Planned primary completion date changed from 1 Aug 2026 to 1 Aug 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top